BFRA News and Press, Biofrontera AG From 05/20/20

Biofrontera AG (BFRA) Q1 2020 Results Earnings Conference Call May 20, 2020 8:00 AM ET Company Participants Pamela Keck - Head, Investor Relations Hermann Lübbert - Chief Executive Officer Thomas Schaffer - Chief Financial Officer Conference Call Participants Bruce J...

Leverkusen, May 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2020 and provided an update on re...

Leverkusen, Germany, May 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or “Biofrontera”), an international biopharmaceutical company, today comments on certain litigation in California state court betwe...

Leverkusen, Germany, May 12, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its unaudited financial results for the first quarter 2020 on Tuesday, May 19, 2020...

Biofrontera Inks New Licensing Deal, Reports FY 2019 Numbers Biofrontera AG ( BFRA ) announced inking a new exclusive licensing deal with Maruho Co. Ltd. of Osaka, Japan. The deal pertains to the development and commercialization of Ameluz in East Asia and Oceania. Under the terms of the c...

Biofrontera AG (BFRA) Q4 2019 Earnings Conference Call April 21, 2020 08:00 ET Company Participants Pamela Keck - Head, Investor Relations Hermann Lübbert - Chief Executive Officer Thomas Schaffer - Chief Financial Officer Conference Call Participants Bruce Jackson - T...

Image source: The Motley Fool. Biofrontera AG   (NASDAQ: BFRA) Q4 2019 Earnings Call Apr 21, 2020 , 8:00 a.m. ET Operator Continue reading

Leverkusen, Germany, April 20, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the full year ended December 31, 2019 and provided an up...

Biofrontera AG (NASDAQ: BFRA ) has signed an exclusive license agreement with Maruho Ltd, Osaka, Japan for Ameluz for all indications in East Asia and Oceania. More news on: Biofrontera AG, Healthcare stocks news, Read more ...

Leverkusen, Germany, April 20, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, has signed today an exclusive license agreement (the "Agreement") ...